FTC Orders Illumina to Divest Cancer Detection Test Maker Grail
The US Federal Trade Commission on Monday ordered Illumina to divest cancer diagnostic test maker Grail, finding that its ownership would stifle competition in the US market for cancer tests.
Reuters Health Information
source https://www.medscape.com/viewarticle/990377?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/990377?src=rss
Comments
Post a Comment